JP4292738B2 - インドール誘導体およびその医薬用途 - Google Patents

インドール誘導体およびその医薬用途 Download PDF

Info

Publication number
JP4292738B2
JP4292738B2 JP2001357400A JP2001357400A JP4292738B2 JP 4292738 B2 JP4292738 B2 JP 4292738B2 JP 2001357400 A JP2001357400 A JP 2001357400A JP 2001357400 A JP2001357400 A JP 2001357400A JP 4292738 B2 JP4292738 B2 JP 4292738B2
Authority
JP
Japan
Prior art keywords
carbons
alkyl
carbon atoms
hydrogen
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001357400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002220391A5 (https=
JP2002220391A (ja
Inventor
敏 坂見
孝治 河合
至幸 前田
拓実 青木
新也 上野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to JP2001357400A priority Critical patent/JP4292738B2/ja
Publication of JP2002220391A publication Critical patent/JP2002220391A/ja
Publication of JP2002220391A5 publication Critical patent/JP2002220391A5/ja
Application granted granted Critical
Publication of JP4292738B2 publication Critical patent/JP4292738B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2001357400A 2000-11-22 2001-11-22 インドール誘導体およびその医薬用途 Expired - Fee Related JP4292738B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001357400A JP4292738B2 (ja) 2000-11-22 2001-11-22 インドール誘導体およびその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000356382 2000-11-22
JP2000-356382 2000-11-22
JP2001357400A JP4292738B2 (ja) 2000-11-22 2001-11-22 インドール誘導体およびその医薬用途

Publications (3)

Publication Number Publication Date
JP2002220391A JP2002220391A (ja) 2002-08-09
JP2002220391A5 JP2002220391A5 (https=) 2005-06-30
JP4292738B2 true JP4292738B2 (ja) 2009-07-08

Family

ID=18828643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001357400A Expired - Fee Related JP4292738B2 (ja) 2000-11-22 2001-11-22 インドール誘導体およびその医薬用途

Country Status (11)

Country Link
US (1) US6770654B2 (https=)
EP (1) EP1342723B1 (https=)
JP (1) JP4292738B2 (https=)
KR (1) KR20030053530A (https=)
CN (1) CN1247591C (https=)
AT (1) ATE402179T1 (https=)
AU (2) AU2408602A (https=)
CA (1) CA2427931A1 (https=)
DE (1) DE60135016D1 (https=)
ES (1) ES2311034T3 (https=)
WO (1) WO2002042309A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324742B2 (en) 2018-03-08 2022-05-10 Victoria Link Ltd. Treatment of demyelinating diseases

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424337A1 (en) * 2002-11-26 2004-06-02 Solvay Pharmaceuticals GmbH 4-hydroxy derivatives of 5,6,9,10-tetrahydro-10-((2-methyl-1h-imidazol-1-yl)methyl)-4h-pyrido-(3,2,1-jk)-carbazol-11(8h)-one
EP1602374A4 (en) * 2003-03-07 2007-03-07 Toray Industries MEANS FOR TREATMENT OF MEDICAMENT / SUBSTANCE DEPENDENCE
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
JPWO2008001859A1 (ja) * 2006-06-30 2009-11-26 学校法人北里研究所 オピオイドδ受容体アゴニスト
EP2149370A1 (en) 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof
IT1390848B1 (it) 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849731A (en) * 1995-09-26 1998-12-15 Toray Industries, Inc. Indole derivatives and medical application thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324742B2 (en) 2018-03-08 2022-05-10 Victoria Link Ltd. Treatment of demyelinating diseases
US12318380B2 (en) 2018-03-08 2025-06-03 Victoria Link Ltd. Treatment of demyelinating diseases

Also Published As

Publication number Publication date
EP1342723A1 (en) 2003-09-10
CA2427931A1 (en) 2002-05-30
EP1342723A4 (en) 2005-02-09
CN1247591C (zh) 2006-03-29
AU2002224086B1 (en) 2006-11-16
ES2311034T3 (es) 2009-02-01
ATE402179T1 (de) 2008-08-15
DE60135016D1 (de) 2008-09-04
AU2002224086B8 (en) 2002-06-03
JP2002220391A (ja) 2002-08-09
US6770654B2 (en) 2004-08-03
CN1486321A (zh) 2004-03-31
US20040019071A1 (en) 2004-01-29
KR20030053530A (ko) 2003-06-28
EP1342723B1 (en) 2008-07-23
AU2408602A (en) 2002-06-03
WO2002042309A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
CN101827819B (zh) 阿片样物质酰胺季铵盐
US20050090519A1 (en) 1-Alkyl-4-(3-substitutedphenyl)piperidines
US5739145A (en) Antitussive agents
JPH054983A (ja) イソキノリノン誘導体、その製造方法およびその誘導体を有効成分として含有する５−ｈｔ３ レセプター拮抗剤
JPH09505030A (ja) ヒドロイソキノリン誘導体
WO1998043978A1 (en) Morphinane derivatives and medicinal use thereof
US10106522B2 (en) Benzimidazole derivatives as antihistamine agents
KR101233289B1 (ko) 지양제
JP4292738B2 (ja) インドール誘導体およびその医薬用途
JP5252391B2 (ja) オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
WO1988007858A1 (en) Sulfinyl and sulfonyl substituted 3-benzazepines
JP3123080B2 (ja) 「インドール誘導体およびその医薬用途」
ITMI951900A1 (it) Derivati idroisochinolinici sostituiti
PT100658A (pt) Derivados de hidro-isoquinolina e processo para a sua preparacao
JPWO1997011948A1 (ja) インドール誘導体およびその医薬用途
JPH1087667A (ja) モルフィナンヒドロキサム酸化合物
JPH0373552B2 (https=)
US4707484A (en) Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
CN112759546B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途
JP2002542247A (ja) モルフィノイド化合物
JPH05247052A (ja) Ｎ−アルキルグルタールイミドの４−（４−ピペリジニル）−チエノ〔３，２−ｃ〕ピリジン誘導体
JPWO1998043978A1 (ja) モルヒナン誘導体及び医薬用途
HK1141295B (en) Quaternary opioid carboxamides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080811

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090317

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090330

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120417

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120417

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees